The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.

ABSTRACT: CD19-directed CAR T-cell therapy with brexucabtagene autoleucel (brexu-cel) has substantially improved treatment outcomes for patients with relapsed/refractory mantle cell lymphoma (r/r MCL). Prolonged cytopenias and infections represent common and clinically relevant side effects. In this multicenter observational study, we describe cytopenias and infections in 103 r/r MCL patients receiving brexu-cel. Furthermore, we report associations between the baseline CAR-HEMATOTOX (HT) score and toxicity events, non-relapse mortality (NRM), and progression-free/overall survival (PFS/OS). At lymphodepletion, 56 patients were HT^low (score 0-1) while 47 patients were HT^high (score ≥2). The HT^high cohort exhibited prolonged neutropenia (median 14 vs. 6 days, p < .001)

SUBMITTER: Rejeski K 

PROVIDER: S-EPMC10659121 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature